“Both the high safety standard and the risk [that] missed ACS poses to patients and clinicians contribute to over-testing, which exposes patients to costs and iatrogenic harm while contributing to ED ...

DALLAS, TX and WASHINGTON, DC — The American Heart Association and the American College of Cardiology have issued a guideline for the management of patients with non-ST-elevation acute coronary ...

With their first update in 5 years, the European Society of Cardiology (ESC) guidelines for non-ST-segment elevation acute coronary syndromes have incorporated several new concepts plus rethinks ...

OAKLAND, Calif.--(BUSINESS WIRE)--Dascena, Inc., a machine learning diagnostic algorithm company that is targeting early disease intervention to improve patient care outcomes, today announced that a ...

A non-ST segment elevation myocardial infarction, also called an NSTEMI or a non-STEMI, is a type of heart attack. While it's often less damaging to your heart than a STEMI, it's still a serious ...

SAN FRANCISCO, California — A small, phase 2 study, with a biomarker test for its primary end point, offers some encouraging hints that the P-selectin antagonist inclacumab may be able to reduce ...

Background Prehospital delays remain critical barriers to timely acute coronary syndrome (ACS) care, particularly for ...

(UPDATED) Patients presenting with non-ST-elevation myocardial infarction treated early with PCI have a lower risk of rehospitalization and death at 30 days compared with patients treated in the ...